Search Results

You are looking at 1 - 10 of 264 items for :

  • "expectancy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Counterpoint: Prostate Cancer Life Expectancy Can Not Be Accurately Predicted From Currently Available Tools

Susan A. McCloskey and Michael R. Kuettel

cancer? Urology 1998 ; 5 : 197 – 202 . 6. Howard DH . Life expectancy and the value of early detection . J Health Econ 2005 ; 24 : 891 – 906 . 7. Yan Y Carvalhal GF Catalona WJ . Primary treatment choices for men with

Full access

Point: TheValue of Predicting Life Expectancy in Men with Clinically Localized Prostate Cancer

Douglass B. Clayton and Donald A. Urban

://www.census.gov/ipc/www/usinterimproj . Accessed June 24, 2007 . 7. Lantz PM Ubel PA . The use of life expectancy in cancer screening guidelines . J Gen Intern Med 2005 ; 6 : 552 – 553 . 8. Johansson JE Holmberg L Johansson S . Fifteen year survival in prostate cancer

Full access

Biobehavioral Factors in Chemotherapy-Induced Nausea and Vomiting

Joseph A. Roscoe, Gary R. Morrow, Jane T. Hickok, Karen M. Mustian, and Abhay R. Shelke

. Self-control expectancy and postsurgical pain: Relationships to previous pain, behavior in past pain, familial pain tolerance models, and personality . J Pain Symptom Manage 1993 ; 8 : 205 – 214 . 6 Scheier MF Matthews KA Owens JF

Full access

A Method for Using Life Tables to Estimate Lifetime Risk for Prostate Cancer Death

Hyung L. Kim, Marvin R. Puymon, Maochun Qin, Khurshid Guru, and James L. Mohler

treated without curative therapy. Elderly patients diagnosed with prostate cancer are at risk for non-prostate cancer mortality. Therefore, an estimate of life expectancy is essential for informed decision-making. Life expectancy is commonly estimated

Full access

Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer

Ayal A. Aizer, Jonathan J. Paly, Anthony L. Zietman, Paul L. Nguyen, Clair J. Beard, Sandhya K. Rao, Irving D. Kaplan, Andrzej Niemierko, Michelle S. Hirsch, Chin-Lee Wu, Aria F. Olumi, M. Dror Michaelson, Anthony V. D’Amico, and Jason A. Efstathiou

-low-risk prostate cancer reflect both the extremely favorable prognosis for these men and the lack of perceived benefit to immediate, definitive treatment. Based on data from the 2007 Social Security Life Table, which indicates that the life expectancy for an

Full access

Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States

Ayal A. Aizer, Xiangmei Gu, Ming-Hui Chen, Toni K. Choueiri, Neil E. Martin, Jason A. Efstathiou, Andrew S. Hyatt, Powell L. Graham, Quoc-Dien Trinh, Jim C. Hu, and Paul L. Nguyen

-risk prostate cancer and a life expectancy of less than 10 years. The purpose of this study was to define, on a large scale, the incidence, risk factors, economic burden, and morbidity related to overly aggressive treatment of patients with low-risk prostate

Full access

Cancer Screening and Surveillance Testing for Older Adult Cancer Survivors

Presented by: Nancy L. Keating

overdiagnoses: when a cancer never progresses (or may even regress), and when a patient has a limited life expectancy and dies of another cause sooner than the cancer would progress and symptoms would appear. “If an overdiagnosed cancer is treated, the patient

Full access

New Developments in the Management of Prostate Cancer

Philip W. Kantoff and James L. Mohler

recommending active surveillance for men with a low risk of prostate cancer and life expectancy less than 10 years and those with a very low risk of cancer and a life expectancy less than 20 years, he said. In 2011, the NCCN Guidelines for prostate cancer

Full access

NCCN Task Force Report: Breast Cancer in the Older Woman

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

assure optimal, individualized treatment of older women with breast cancer is increasing. However, several obstacles to accomplishing this task exist. Functional status, social support, the presence of comorbidities, and life expectancy must be considered

Full access

Reflecting the Debates of Updating the Prostate Cancer Guidelines

James L. Mohler

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of the NCCN. References 1. Howard D H . Life expectancy and the value of early